Blood Podcast – “Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; Insights on cHL genetics, through the lens of ctDNA

Date: September 4, 2025
Host: American Society of Hematology
Summary by: Blood Podcast Summarizer

Episode Overview

This episode of the Blood Podcast highlights three significant studies recently published in Blood. Each study tackles a key challenge at the interface of molecular biology and clinical hematology, offering innovative insights and potential therapeutic advances:

1. The metabolic dependency of Tet2-mutant hematopoietic stem and progenitor cells (HSPCs) on NCOA4-mediated ferritinophagy.
2. A phase 1/2 trial of WU-CAR-T007, a CD7-targeted, off-the-shelf CAR-T cell therapy for relapsed/refractory T cell leukemia/lymphoma.
3. Comprehensive genetic profiling of classical Hodgkin lymphoma (cHL) using circulating tumor DNA (ctDNA).

1. Iron Metabolism and Clonal Expansion: NCOA4-mediated Ferritinophagy in Tet2-mutant HSPCs

Discussion: 00:20–09:13

Key Points

• Research Focus: The study ("An in vivo barcoded CRISPR Cas9 screen identifies NCOA4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesis") led by Justin Loke and colleagues identifies NCOA4, a ferritin cargo receptor, as a critical dependency for clonal expansion of Tet2-mutant HSPCs.
• Background:
  • Tet2 is an iron-dependent enzyme key for DNA demethylation.
  • Loss-of-function Tet2 mutations are common in clonal hematopoiesis of indeterminate potential (CHIP) and myeloid malignancies, often providing a growth advantage to HSPCs.
• Technological Innovation:
  • Authors developed a barcoded, lentiviral CRISPR-Cas9 platform. This allowed them to track clonal growth and precisely identify gene dependencies in mouse models.
• Findings:
  • NCOA4 Required for Clonal Outgrowth: Tet2 knockout HSPCs, but not wild-type, rely on NCOA4 for expansion.
  • Mechanism: NCOA4 mediates ferritinophagy—autophagy-dependent lysosomal degradation of ferritin—maintaining a pool of labile iron necessary for increased mitochondrial ATP production in mutant cells.
  • Intervention:
    • Genetic deletion of NCOA4 impairs Tet2-deficient HSPC expansion without harming wild-type.
    • Ironomycin, an iron-sequestering compound, inhibits ferritinophagy and curbs mutant cell outgrowth.
• Therapeutic Implications: Targeting ferritinophagy may selectively impact Tet2-mutant clones, hinting at potential strategies to prevent or delay myeloid malignancies’ progression.

Memorable Quotes

• “By targeting ferritinophagy, it may be possible to iron out our problems with Tet2 mutant cells.”
  — Host, referencing commentary by Leroux and Tamberini (08:50)

• “This work highlights enhanced mitochondrial metabolism as a hallmark of clonal hematopoiesis. It also suggests that metabolic vulnerabilities may be therapeutically exploitable.”
  — Host summarizing commentary (09:00)

Commentary & Broader Context

• References to recent supporting studies: Ferritinophagy has also been identified as a critical dependency for leukemic stem cells in AML models.
• Broader Implications: Enhanced mitochondrial metabolism is emerging as a universal hallmark of clonal hematopoiesis that can be exploited for therapy.

2. WU-CAR-T007: A “License to Kill” in T Cell Leukemia and Lymphoma

Discussion: 09:16–18:23

Key Points

• Research Focus: “A phase 1/2 trial of anti-CD7 allogeneic WU-CAR-T007 in patients with relapsed/refractory T cell malignancies” by Armin Gobadi and colleagues.
• Clinical Challenge:
  • T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) relapsed/refractory cases have dismal outcomes—median survival ~6 months, 5-year survival <7%.
  • Limited therapeutic options; only nilarabine has been approved since 2005, with modest efficacy and notable toxicity.
• Therapy Innovation:
  • CD7 as a Target: Expressed in >95% of T-ALL/LBL cases and persists throughout disease.
  • Engineering Solutions:
    • Traditional CAR-T is hampered by product contamination (malignant cells) and “fratricide” (CAR-T killing of normal T cells).
    • WU-CAR-T007 is an allogeneic, off-the-shelf product from healthy donors, CRISPR-edited to delete CD7 (prevents fratricide), then transduced with the anti-CD7 CAR.
• Clinical Results:
  • Participants: Median of 4 prior therapies; 40% post-transplant relapse; 13 received recommended dose.
  • Efficacy:
    • ORR: 91% (11 evaluable patients)
    • CR/CRi: 73%
    • Durable responses, especially as a bridge to transplant (8 patients transitioned to HSCT).
  • Safety:
    • Cytokine release syndrome (CRS): 88.5% (19.2% grade 3-4)
    • Neurotoxicity (ICANS): 7.7% (both grade 1)
    • One grade 2 GVHD and one grade 2 HLH-like syndrome.
  • Persistence: Limited, but allows for recovery of endogenous CD7+ T and NK cells.

Memorable Quotes

• “This study offers the promise of a new treatment option for patients with otherwise dismal outcomes.”
  — Host, summarizing commentary by Naik and Momonkin (16:45)

• “As an off-the-shelf product, WU-CAR-T007 can address manufacturing challenges associated with autologous CAR T, offering patients an immediate therapeutic option.”
  — Host (17:02)

Commentary & Broader Context

• Bridge to Transplant: WU-CAR-T007 shows particular promise as an effective bridge to HSCT.
• Off-the-shelf Caveats:
  • Functional persistence is limited, immune rejection remains a challenge.
  • “The limited duration of WU-CAR-T007 activity allowed for a more rapid rebound of endogenous CD7 T and NK cells.” (17:38)
• Future Directions: Focus on optimizing sequencing, improving persistence, and mitigating immune rejection to achieve long-term cures in T-ALL/LBL.

3. Dissecting Classical Hodgkin Lymphoma (cHL) Genetics Using ctDNA

Discussion: 18:28–27:00

Key Points

• Research Focus: “A comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA,” by Maria Cristina Perosa and colleagues.
• Background:
  • Studying cHL genetics is challenged by the scarcity (<0.1%) of Hodgkin/Reed-Sternberg cells in tumor tissue.
  • ctDNA Solution: Plasma contains a higher concentration of tumor DNA than tissue, permitting deeper molecular profiling.
• Findings:
  • Genetic Subtypes:
    • Subtype 1 (64%): High mutational load, AID (activation induced cytidine deaminase)-related mutation signatures, microsatellite instability.
    • Subtype 2 (36%): Marked by chromosomal instability, high somatic copy number alteration burden.
  • Prognostic Biomarkers:
    • Whole genome duplication (WGD): More common in cHL; associated with shorter PFS and lower cure rates—can serve as a genetic biomarker.
  • Non-coding Regulatory Mutations:
    • 83% of tumors had DNA changes in non-coding regions, often linked to AID mutagenesis.
    • A notable hotspot in BCL6, with ~30% of cases showing alterations.
  • Therapeutic Implications:
    • Disrupting BCL6 de-repressed key gene networks and impaired cell proliferation, suggesting BCL6 vulnerability.
  • Microenvironment Insights:
    • Neoantigen load correlates with immune microenvironment phenotype (macrophage- vs T cell-enriched), shaping disease biology.
  • Clinical Utility:
    • ctDNA may clarify ambiguous PET/CT responses—could function as a “liquid biopsy” alternative for monitoring residual disease.
• Big Picture Conclusions:
  • Genetic subtypes in cHL hinge more on mechanisms of chromosomal instability than on functional mutation clustering.
  • Key factors (WGD, BCL6 alterations, neoantigen load) shape both disease pathophysiology and patient outcomes.

Memorable Quotes

• “This new work provides novel and complex insights into CHL genetics... It’s a comprehensive analysis of CHL genetics that shows for the first time AID-mediated mutagenesis at non coding regulatory regions with substantial consequences on gene expression regulation in CHL.”
  — Host, referencing Andrej Havernek’s commentary (25:56)

• “This discovery reveals an important overlap of CHL and diffuse large B cell lymphoma biology. The current study clearly documents an important novel non coding regulatory mutational hotspot in the BCL6 gene.”
  — Host summarizing Havernek (26:12)

Commentary & Broader Context

• Clinical Application:
  • ctDNA tracking may soon guide real-time risk stratification and tailoring of therapy in cHL, but requires robust prospective validation and standardized methodology.
• Ongoing Clinical Trials:
  • Trials are underway to test ctDNA-guided treatment adjustments.
  • Technical standards for ctDNA are urgently needed across all analytical stages.

Timestamps for Key Segments

| Segment | Timestamps | |-------------------------------------------------------------------|-----------------| | Main episode topic overview | 00:02–01:20 | | NCOA4 and ferritinophagy in Tet2-mutant HSPCs | 01:20–09:13 | | WU-CAR-T007 for T cell leukemia/lymphoma | 09:16–18:23 | | ctDNA profiling in classical Hodgkin lymphoma | 18:28–27:00 |

Engaging Moments & Speaker Style

• The host presents scientific findings with clarity and an engaging sense of humor (“iron out our problems with Tet2 mutant cells”).
• Frequent attributions to commentary authors add depth and context.
• The tone is professional but accessible, skillfully guiding listeners through both technical details and clinical significance.

Bottom Line

• Iron metabolism, CAR-T cell engineering, and liquid biopsy genetics are each defining new frontiers in hematology.
• This episode showcases how molecular insights and innovative technology—whether barcoded CRISPR screens, off-the-shelf gene-edited cells, or ctDNA sequencing—are transforming diagnosis and therapy for hematologic diseases.
• As the field advances, translating these discoveries into tailored therapies and real-time monitoring holds great promise for improving outcomes.

(For original articles and author affiliations, see BloodJournal.org and episode show notes.)